What this combination treatment involves

If a specialist recommends ChondroFiller combined with BMAC, the appointment involves two distinct components — a scaffold and a biological concentrate — delivered together in a single outpatient visit under ultrasound guidance.

ChondroFiller (manufactured by Meidrix Biomedicals, CE Class III) is an acellular injectable collagen scaffold. It arrives as a two-part liquid; once placed into the cartilage defect under image guidance, the components cross-link and the matrix self-gels within minutes, conforming to the contours of the defect without any shaping by the clinician.

BMAC — bone marrow aspirate concentrate — is the patient's own biological material, drawn from the iliac crest (the back of the pelvic bone) at the same appointment. The marrow is then processed and concentrated before being mixed with the ChondroFiller liquid.

The two materials have different roles. ChondroFiller provides a stable three-dimensional matrix — a physical home for repair cells. BMAC supplies mesenchymal stem cells (MSCs) and growth factors that support the body's own repair processes within that matrix. Neither component alone does what the combination does.

The complete pathway — marrow harvesting, preparation, and ultrasound-guided placement into the defect — takes place within the same outpatient appointment, without surgery, incisions, or a theatre admission.

Why pairing a scaffold with bone-marrow cells may work better

The central problem with injecting bone marrow concentrate directly into a cartilage defect is timing: the joint is a dynamic fluid environment, and synovial fluid turnover clears injected material from the repair site within hours. However rich the cellular payload, cells that cannot remain in contact with the defect cannot contribute meaningfully to repair.

ChondroFiller addresses this not by altering the biology of the cells, but by changing the environment they land in. Mixed with the BMAC liquid before injection, the two-component collagen system self-gels inside the defect, physically trapping the MSC-containing concentrate within the three-dimensional matrix. The result is what clinicians describe as acellular matrix-induced chondrogenesis — a scaffold that retains the patient's own progenitor cells precisely where repair tissue needs to form, rather than relying on those cells to stay put in a fluid-filled space.

Once retained, MSCs within the BMAC are proposed to support the body's own repair processes through three mechanisms: differentiating into chondrocytes, synthesising extracellular matrix, and modulating local inflammation. Laboratory and early clinical work supports this sequence, though the relative contribution of each pathway continues to be investigated.

The combination also removes the need for microfracture. By avoiding deliberate breach of the subchondral bone plate, this approach preserves the biomechanical foundation of the joint — a structural advantage over marrow-stimulation techniques, where plate disruption is a recognised driver of longer-term failure.

Patients typically assessed for this combination

The combination is most commonly considered in patients with a discrete, focal cartilage defect — a clearly bounded area of full-thickness damage rather than the widespread joint surface deterioration seen in osteoarthritis. Diffuse OA is outside the supported indication; the scaffold requires a defined cavity to gel within and retain the biological concentrate.

Defect size offers a useful reference point. The 2011 Gobbi study enrolled patients with grade IV lesions averaging 9.2 cm² — already large by cartilage-repair standards — and recorded meaningful clinical and structural outcomes at two years. For patients with a focal lesion in a broadly healthy joint, that figure indicates even sizeable full-thickness defects may sit within the candidate window.

BMAC augmentation is typically added when a specialist judges that the patient's own progenitor cell supply is unlikely to be sufficient for scaffold-alone repair. Factors informing that judgement include patient age, defect depth and size, and whether previous procedures — particularly earlier marrow stimulation — may have reduced local cell availability from the subchondral bone.

Published evidence covers knee, hip, and small-joint applications, with the knee representing the most thoroughly studied population. Suitability across all these factors is determined through specialist assessment, including MRI and clinical review, rather than any single threshold.

What the clinical evidence shows

The clearest direct evidence for this combination comes from a 2011 prospective study by Gobbi and colleagues (PMC4300809). Fifteen patients with grade IV full-thickness knee defects — mean lesion size 9.2 cm², well above what many techniques can reliably address — underwent one-step repair with BMAC delivered into a collagen I/III matrix. At two-year follow-up, all clinical scores had improved significantly (p<0.005), MRI confirmed hyaline-like tissue coverage across the defect, and biopsy findings were consistent with hyaline-like rather than fibrocartilage. No adverse events were recorded.

The scaffold's own track record adds important context. Across four independent knee studies, ChondroFiller alone produces approximately 30-point improvements in IKDC score — more than double the established minimum clinically important difference of 16.7 points. In the Jerosch et al. prospective post-market follow-up study, the mean improvement reached 32.4 IKDC points, sustained at three-year review, with patients achieving a functional score of 80.1. Structural imaging corroborates this: MOCART scores of 81.6–84.3 indicate greater than 80% defect fill and good integration with native cartilage, progressively maturing from approximately 65 at four weeks as the matrix consolidates.

A 2024 study by Whyte and colleagues (PubMed 39491512) extends the picture, reporting sustained clinical outcomes and maintained cartilage repair in patients treated with a one-step scaffold-plus-BMAC approach at long-term follow-up.

The evidence base carries real limits. Independent randomised controlled trials comparing the combination directly against scaffold alone remain sparse, and some of the outcome data derives from post-market studies with industry involvement. Optimal BMAC cell concentration protocols are not yet standardised, and the combination carries its own documented complications — considered in the following section.

How this compares with other repair options

Specialists weighing cartilage repair options generally consider three comparisons when ChondroFiller with BMAC is on the table.

Versus microfracture. Marrow stimulation produces fibrocartilage — a mechanically inferior tissue that may deteriorate over time — and deliberately breaches the subchondral plate. That breach is associated with cyst formation and altered load distribution, both drivers of long-term failure. The scaffold-plus-BMAC approach recruits mesenchymal cells without disturbing the bone plate, and the Gobbi study (PMC4300809) confirmed hyaline-like repair tissue histologically in patients who had not undergone microfracture.

Versus ACI. Autologous chondrocyte implantation remains a valid technique for medium and large defects, producing comparable hyaline-like tissue quality. The procedural difference is significant: ACI requires two separate stages — cell harvest, then implantation — whereas ChondroFiller with BMAC is completed in one appointment. Reported complication rates for ACI reach approximately 17%, with reoperation figures of up to 37% in some series; published ChondroFiller data record a complication rate of approximately 0% and reoperation of 3–8%.

Versus scaffold alone. A 2023 meta-analysis found that BMAC augmentation yields marginally better short-term outcomes than acellular scaffold alone, though differences did not consistently reach clinical significance. Long-term comparative data remain limited.

As raised in the evidence section, known complications of biologically augmented scaffold repair include graft hypertrophy, arthrofibrosis, graft hypotrophy, and dislodgement. A specialist consultation is the appropriate setting for weighing these risks against individual patient circumstances.

Finding a specialist and questions worth asking

Three questions are worth raising at any initial consultation on this combination.

Does the specialist offer ChondroFiller as an injectable scaffold pathway, with BMAC harvested and concentrated in the same appointment? Some centres separate the two steps; confirming this upfront avoids an unnecessary return visit and ensures the components are available together.

How will BMAC cell concentration be determined? There is currently no single standardised protocol — aspirate volume, centrifugation method, and target cell count vary between centres. A confident specialist will explain their approach plainly and in advance.

What does the imaging show? MRI grade and defect geometry are the primary determinants of whether this combination is appropriate at all. Defect size, depth, and location each affect suitability — and the answer may point toward a different pathway entirely.

On timelines: clinical score improvements in published studies are typically measured between six months and three years; early hyaline-like tissue appearance on follow-up MRI is a positive indicator that repair is consolidating as intended.

Search MSK lists specialists across the UK who offer ChondroFiller and related cartilage injection therapies — filter by region and specialty to find a clinician near you. For most patients, the consultation itself is where a personalised decision becomes possible: the published evidence sets a framework; a clinical assessment of the individual's imaging, joint health, and activity goals determines whether it applies.